Zydus Launches PEPAIR for Respiratory Issues

1 Minute Read Listen to Article
Share:    

Feb 17, 2026 15:30

x
Zydus Lifesciences launches PEPAIR, India's first affordable OPEP device for COPD, Asthma, and Bronchiectasis patients. Improves breathing.
Zydus Launches PEPAIR for Respiratory Issues
Photograph: Courtesy Zydus.
New Delhi, Feb 17 (PTI) Zydus Lifesciences on Tuesday said it has launched a device to help clear congestion, support effective mucous clearance, and improve breathing in patients with COPD, Asthma, and Bronchiectasis.

The company has launched PEPAIR, India's first affordable Oscillating Positive Expiratory Pressure (OPEP) device, according to a statement.

More than 90 lakh patients suffer from chronic respiratory conditions in India, it added.

Chronic mucous hypersecretion is a common problem amongst these patients that requires an airway clearance solution for everyday care, the drug firm said.


PEPAIRTM is being launched in agreement with AeroDel Technology Innovations, an Indian medical device company focused on simplifying inhalation through drug-delivery, pulmonary rehabilitation, it said.

"With PEPAIR, India's first affordable OPEP device, we are introducing a drug-free, handheld solution designed to support better breathing for patients with COPD, asthma and bronchiectasis," Zydus Lifesciences Managing Director Sharvil Patel said.

OPEP, a therapy using a handheld, translucent device that creates pressure and vibrations during exhalation to loosen mucous, open airways, and promote clearance, it said.

Respiratory diseases are rising sharply in India due to a combination of extreme and persistent air pollution, climate-driven changes in allergens and ozone, rapid urbanisation, and delayed diagnosis of chronic lung conditions. PTI MSS BAL

BAL
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback